文献速递血栓与止血

肾细胞癌瘤栓患者抗凝治疗结局:一项系统综述

Outcomes of anticoagulation treatment for renal cell carcinoma tumor thrombi: a systematic review.
PubMed 文献 · J Thromb Haemost · 2025-11-04

该系统综述纳入6项观察性研究共659例肾细胞癌伴瘤栓患者,评估抗凝治疗与静脉血栓栓塞、大出血及动脉血栓栓塞的关系。抗凝使用率为3.9%至50%,两项研究报告抗凝患者静脉血栓栓塞发生率低于未抗凝患者,但所有研究存在显著偏倚风险,证据尚不确定。

要点

  • 抗凝患者1年静脉血栓栓塞发生率为7.3%,未抗凝患者为20%。
  • 抗凝患者1年大出血发生率为12%,未抗凝患者为19%。
  • 所有纳入研究存在显著偏倚风险,证据尚不确定。

核心结论

  • 肾细胞癌伴瘤栓患者抗凝可能降低静脉血栓栓塞风险,但抗凝与未抗凝患者出血风险均高,当前证据因研究异质性和偏倚风险尚不确定。

研究设计与样本

  • 系统综述,纳入6项观察性研究共659例肾细胞癌伴瘤栓的门诊患者,排除患者数少于30例的研究及未按结局分层报告抗凝状态的研究,检索PubMed等数据库,采用苏格兰校际指南网络偏倚质量评估工具评估偏倚风险。

主要发现

  • 抗凝使用率范围为3.9%至50%。
  • 两项研究报告抗凝患者静脉血栓栓塞发生率低于未抗凝患者:1年后为7.3%(1.2-21)vs 20%(6.9-37),2年后为18%(1.5-49)vs 24%(14-36)。
  • 抗凝患者大出血发生率1年后为12%(2.8-27),2年后为33%(8.2-60)。
  • 未抗凝患者大出血发生率1年后为19%(6.6-36),2年后为12%(5.1-22)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有纳入研究均存在显著偏倚风险。
  • 纳入研究均非管理性研究。
  • 结局指标的置信区间宽。
  • 当前证据因研究异质性和偏倚风险尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with renal cell carcinoma (RCC) and tumor thrombus (TT) are at significant risk of venous thromboembolism (VTE). OBJECTIVES: This systematic review aimed to assess the role of anticoagulation in ambulatory patients with RCC and TT. METHODS: Inclusion criteria were diagnosis of RCC with TT, reporting of VTE, major bleeding and/or arterial thromboembolism, as well as exposure to anticoagulation. Studies with <30 patients were excluded. Studies were also excluded if anticoagulation status was not reported per outcome stratum. A comprehensive search was conducted in PubMed and other databases. Risk of bias was assessed in accordance with the Scottish Intercollegiate Guidelines Network bias quality assessment tool. RESULTS: Six observational studies containing 659 patients were included. All studies had considerable risk of bias. Anticoagulation use ranged from 3.9% to 50%. Two studies reported a lower VTE incidence in anticoagulated patients than in non-anticoagulated patients: 7.3% (1.2-21) vs 20% (6.9-37) after 1 year, and 18% (1.5-49) vs 24% (14-36) after 2 years. In anticoagulated patients, major bleeding incidence was 12% (2.8-27) after 1 year and 33% (8.2-60) after 2 years. For non-anticoagulated patients the incidence was 19% (6.6-36) after 1 year and 12% (5.1-22) after 2 years. Importantly, none of the studies were management studies, and confidence intervals of our outcomes were wide. CONCLUSION: Anticoagulation in patients with RCC with TT may lower VTE risk. Bleeding risk is high in both anticoagulated as well as non-anticoagulated patients. Current evidence remains inconclusive due to study heterogeneity and risk of bias.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Akerboom B, Martens ESL, Kaptein FHJ, et al. Outcomes of anticoagulation treatment for renal cell carcinoma tumor thrombi: a systematic review. J Thromb Haemost. 2025. PMID: 41197810. doi:10.1016/j.jtha.2025.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。